Verrica Pharmaceuticals Inc. (VRCA)
VRCANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.56
-0.1600 (-4.30%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $61.16m
- P/E
- –
- EPS, last 4 quarters
- $-2.13
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.08 to $9.82
- Average volume
- –
- Previous close
- $3.72
Analysts
4 coveringBuy3 buy, 1 hold, 0 sell
Targets a year out average $13.67, +284.0% from here
Earnings
next estimate $-0.4100Next report
Dec 2025
-27.3%
Mar 2026
+25.0%
Jun 2026
–
Sep 2026
-16.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $14.34m | $5.09m | $5.02m | $5.86m |
| Gross profit | $13.23m | $3.69m | $4.13m | $4.98m |
| Operating income | $1.63m | -$7.19m | -$9.71m | -$13.10m |
| Net income | -$274.0k | -$8.07m | -$9.68m | -$13.15m |
Last four quarters: revenue $30.32m, margin -102.8%, free cash flow –
News
8 latest- Verrica (VRCA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 12 hours ago
- Verrica Pharma Gains: What Is The Buzz? RTTNews · Aug 19, 2026
- Verrica (VRCA) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 13, 2026
- Verrica Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat · Aug 7, 2026
- Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 6, 2026
- Verrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts RTTNews · Jun 22, 2026
- Verrica (VRCA) Q1 2026 Earnings TranscriptThe Motley Fool · May 13, 2026
- Verrica Pharmaceuticals Q1 Earnings Call HighlightsMarketBeat · May 12, 2026
The company
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica's product YCANTH (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- verrica.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.